Anti-inflammatory cytokines and cytokine antagonists

被引:66
作者
Standiford, TJ [1 ]
机构
[1] Univ Michigan, Sch Med, Dept Med, Div Pulm & Crit Care Med, Ann Arbor, MI 48109 USA
关键词
D O I
10.2174/1381612003400533
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cytokines are critical mediators of protective host responses, including defense against microbial invasion and tumorigenesis. However, the production of specific proinflammatory cytokines must be tightly regulated and compartmentalized to prevent the overzealous expression of these molecules that can culminate in unabated inflammation and tissue injury. Cytokine production and/or biologic effects can be inhibited by a variety of endogenous molecules, including antiinflammatory cytokines, soluble cytokine receptors, and receptor antagonist proteins. Additionally, synthetic molecules have been constructed to selectively block the synthesis, post-translation processing, or receptor binding of proinflammatory cytokines. Relevant anti-inflammatory cytokines and cytokine inhibitors (both endogenous and synthetic) will be the subject of this review, with a particular emphasis on those anti-inflammatory cytokines and cytokine inhibitors that have been used experimentally or clinically in the treatment of diseases that are believed to be mediated by excessive proinflammatory cytokine responses.
引用
收藏
页码:633 / 649
页数:17
相关论文
共 146 条
[91]   Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein [J].
Moreland, LW ;
Baumgartner, SW ;
Schiff, MH ;
Tindall, EA ;
Fleischmann, RM ;
Weaver, AL ;
Ettlinger, RE ;
Cohen, S ;
Koopman, WJ ;
Mohler, K ;
Widmer, MB ;
Blosch, CM .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) :141-147
[92]  
Muchamuel T, 1997, J IMMUNOL, V158, P2898
[93]  
Müller-Ladner U, 1999, ARTHRITIS RHEUM, V42, P490, DOI 10.1002/1529-0131(199904)42:3<490::AID-ANR14>3.0.CO
[94]  
2-L
[95]  
MULLIN JM, 1990, CANCER RES, V50, P2172
[96]   IL1B gene polymorphisms influence the course and severity of inflammatory bowel disease [J].
Nemetz, A ;
Nosti-Escanilla, MP ;
Molnár, T ;
Köpe, A ;
Kovács, A ;
Fehér, J ;
Tulassay, Z ;
Nagy, F ;
García-González, MA ;
Peña, AS .
IMMUNOGENETICS, 1999, 49 (06) :527-531
[97]   Involvement of interleukin-4 and -10 in inflammatory bowel disease [J].
Nielsen, OH ;
Koppen, T ;
Rudiger, N ;
Horn, T ;
Eriksen, J ;
Kirman, I .
DIGESTIVE DISEASES AND SCIENCES, 1996, 41 (09) :1786-1793
[98]   Anticytokine therapy in autoimmune diseases [J].
Nishimoto, N ;
Kishimoto, T ;
Yoshizaki, K .
INTERNAL MEDICINE, 1999, 38 (02) :178-182
[99]   INTERLEUKIN-1 RECEPTOR ANTAGONIST REDUCES MORTALITY FROM ENDOTOXIN-SHOCK [J].
OHLSSON, K ;
BJORK, P ;
BERGENFELDT, M ;
HAGEMAN, R ;
THOMPSON, RC .
NATURE, 1990, 348 (6301) :550-552
[100]   Interleukin 6 plays a key role in the development of antigen-induced arthritis [J].
Ohshima, S ;
Saeki, Y ;
Mima, T ;
Sasai, M ;
Nishioka, K ;
Nomura, S ;
Kopf, M ;
Katada, Y ;
Tanaka, T ;
Suemura, M ;
Kishimoto, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (14) :8222-8226